Axsome insider plans sale of 45,004 shares

Axsome Therapeutics insider Herriot Tabuteau has filed a Form 144 indicating an intention to sell up to 45,004 shares of common stock through Goldman Sachs & Co. LLC, with an approximate sale date of August 5, 2026 on NASD.

Rhea-AI Filing Summary

Axsome Therapeutics insider Herriot Tabuteau has filed a Form 144 indicating an intention to sell up to 45,004 shares of common stock through Goldman Sachs & Co. LLC, with an approximate sale date of August 5, 2026 on NASD. The filing lists the shares as originally acquired on March 15, 2017 as compensation via stock options, with the planned transaction structured as a cashless exercise / same-day sale.

The disclosure also notes prior open-market activity during the past three months, including sales of 24,835 shares of common stock on June 9, 2026 and 24,833 shares on July 1, 2026, each with multi‑million market values. Shares outstanding are listed as 51,459,766, providing context for the scale of the planned sale.

Key Figures

Shares to be sold: 45,004 shares Aggregate market value of planned sale: 9,579,101.4 Shares outstanding: 51,459,766 shares +4 more

7 metrics

Shares to be sold 45,004 shares Maximum common stock shares indicated for sale on or about August 5, 2026

Aggregate market value of planned sale 9,579,101.4 Listed aggregate market value of 45,004 shares of common stock

Shares outstanding 51,459,766 shares Common stock shares outstanding, provided as context in the Form 144

Prior sale 1 24,835 shares Common stock sold on June 9, 2026 with market value 5,950,195.3

Prior sale 1 market value 5,950,195.3 Aggregate market value for 24,835 shares sold on June 9, 2026

Prior sale 2 24,833 shares Common stock sold on July 1, 2026 with market value 6,002,352.15

Prior sale 2 market value 6,002,352.15 Aggregate market value for 24,833 shares sold on July 1, 2026

Key Terms

Form 144, cashless exercise, same-day sale, aggregate market value

4 terms

Form 144 regulatory

"Herriot Tabuteau has filed a Form 144 indicating an intention to sell"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

cashless exercise financial

"Compensation -- Cashless exercise / same-day sale"

A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.

same-day sale financial

"Compensation -- Cashless exercise / same-day sale"

aggregate market value financial

"Aggregate market value of 45,004 shares of common stock"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filed for AXSM disclose about planned share sales?

The Form 144 discloses a plan to sell up to 45,004 shares of Axsome Therapeutics common stock through Goldman Sachs & Co. LLC, with an approximate sale date of August 5, 2026 on NASD.

Who is the reporting person in the AXSM Form 144 filing and what is being sold?

The reporting person is Herriot Tabuteau, who has indicated an intent to sell up to 45,004 shares of Axsome Therapeutics common stock, originally acquired as compensation via stock options on March 15, 2017.

How were the AXSM shares in this Form 144 originally acquired?

The shares covered by the Form 144 were acquired as compensation through stock options on March 15, 2017. The planned transaction is described as a compensation -- cashless exercise / same-day sale by the issuer.

What recent AXSM stock sales by Herriot Tabuteau are disclosed in the past 3 months?

The filing lists prior sales of 24,835 shares of common stock on June 9, 2026 and 24,833 shares on July 1, 2026, each associated with multi‑million market values of the shares sold.

How many AXSM shares are outstanding according to this Form 144 filing?

The Form 144 lists 51,459,766 shares of Axsome Therapeutics common stock as outstanding. This figure provides context for evaluating the relative size of the planned sale of up to 45,004 shares.

Which broker is handling the planned AXSM share sale in this Form 144?

The planned sale of up to 45,004 shares of Axsome Therapeutics common stock is listed as being handled by Goldman Sachs & Co. LLC, located at 200 West Street, New York, NY 10282.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/05/2026 - 06:04 PM Accepted by SEC EDGAR 08/05/2026 - 06:04 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001219927
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Axsome Therapeutics, Inc.
SEC File Number	001-37635
Address of Issuer	One World Trade Center 29th Floor New York NEW YORK 10007
Phone	1-212-332-3241
Name of Person for Whose Account the Securities are To Be Sold	Herriot Tabuteau
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	45004	9579101.4	51459766	08/05/2026	NASD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/15/2017	Acquired as compensation -- Stock Options	The Issuer			45004	03/15/2017	Compensation -- Cashless exercise / same-day sale

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Herriot Tabuteau One World Trade Center 29th Floor New York NY 10007	Common Stock	06/09/2026	24835	5950195.3
Herriot Tabuteau One World Trade Center 29th Floor New York NY 10007	Common Stock	06/09/2026	24835	6020552.85
Herriot Tabuteau One World Trade Center 29th Floor New York NY 10007	Common Stock	07/01/2026	24833	6002352.15
Herriot Tabuteau One World Trade Center 29th Floor New York NY 10007	Common Stock	07/01/2026	24833	5929877.04

144: Remarks and Signature

Remarks	The sales of shares set forth herein are made in connection with a selling plan dated 3/10/2026, that is intended to comply with Rule 10b5-1(c).
Date of Notice	08/05/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/10/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Goldman Sachs & Co. LLC on behalf of Herriot Tabuteau
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)